Everything we've seen

1. ?Sep 14, 3:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

2. !Sep 14, 3:20 PMsignalseverity 0.10

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

3. ?Sep 14, 3:20 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

4. !Sep 14, 3:20 PMsignalseverity 0.10

   Agent 5 — Dip Buyer (Evolving) — dip_skipped

   No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

5. ?Sep 14, 2:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

6. !Sep 14, 2:20 PMsignalseverity 0.10

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

7. ?Sep 14, 2:20 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

8. !Sep 14, 2:20 PMsignalseverity 0.10

   Agent 5 — Dip Buyer (Evolving) — dip_skipped

   No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

9. ?Sep 14, 1:20 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

10. !Sep 14, 1:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

11. ?Sep 14, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

12. !Sep 14, 1:20 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

13. ?Sep 14, 12:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

14. !Sep 14, 12:20 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

15. ?Sep 14, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

16. !Sep 14, 12:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

17. ?Sep 14, 11:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

18. !Sep 14, 11:21 AMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

19. ?Sep 14, 11:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

20. !Sep 14, 11:21 AMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

21. ?Sep 14, 10:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

22. !Sep 14, 10:21 AMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

23. ?Sep 14, 10:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

24. !Sep 14, 10:21 AMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

25. ?Sep 14, 7:01 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

26. !Sep 14, 7:01 AMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

27. ?Sep 14, 7:00 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

28. !Sep 14, 7:00 AMsignalseverity 0.11

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

29. ?Sep 11, 6:04 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    ILMN is down ~10.9% from its 30-day high with no company-specific negative news headlines or materially adverse SEC filings in the window — the 8-Ks filed in August carry no disclosed metrics suggesting deterioration. The drawdown appears to be predominantly macro-driven, as the elevated 5-year forward inflation rate (T5YIFR at 1.8σ above trend) signals rate-sensitivity headwinds that weigh broadly on growth/biotech names like Illumina. As a genomics sequencing leader with a durable competitive moat, the company's fundamental soundness is not in question, but the macro rate environment introduces meaningful near-term pressure on valuation multiples.

30. !Sep 11, 6:04 PMsignalseverity 0.11

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    ILMN is down ~10.9% from its 30-day high with no company-specific negative news headlines or materially adverse SEC filings in the window — the 8-Ks filed in August carry no disclosed metrics suggesting deterioration. The drawdown appears to be predominantly macro-driven, as the elevated 5-year forward inflation rate (T5YIFR at 1.8σ above trend) signals rate-sensitivity headwinds that weigh broadly on growth/biotech names like Illumina. As a genomics sequencing leader with a durable competitive moat, the company's fundamental soundness is not in question, but the macro rate environment introduces meaningful near-term pressure on valuation multiples.

31. !Sep 11, 6:00 PMsignal

    Agent 1 — Immutable — insufficient_capital

32. ✓Sep 11, 6:00 PMdecisionacted

    Agent 2 — Adaptive — entry

    Stage 2: close $206.45 > MA150 $158.70 (+30.1%), MA rising, 10.9% off 52w high, vol 1.39× avg

33. ?Sep 11, 4:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

34. !Sep 11, 4:20 PMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

35. ?Sep 11, 4:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

36. !Sep 11, 4:20 PMsignalseverity 0.11

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

37. ?Sep 11, 3:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

38. !Sep 11, 3:20 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

39. ?Sep 11, 3:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

40. !Sep 11, 3:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

41. ?Sep 11, 2:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

42. !Sep 11, 2:21 PMsignalseverity 0.11

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

43. ?Sep 11, 2:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

44. !Sep 11, 2:21 PMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

45. ?Sep 11, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

46. !Sep 11, 1:20 PMsignalseverity 0.11

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

47. ?Sep 11, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

48. !Sep 11, 1:20 PMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

49. ?Sep 11, 12:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

50. !Sep 11, 12:21 PMsignalseverity 0.11

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ILMN is down 10.5% from its 30-day high with no explanatory news headlines and only empty-metric 8-K filings, suggesting the drop is macro/sector-driven rather than a confirmed fundamental impairment. However, the setup carries meaningful headwinds: a Director (Keith Meister) executed five large insider sales totaling ~$30.6M on a single day (Aug 27), which is a notable negative signal even accounting for possible 10b5-1 plan execution. The health care sector is underperforming SPY by ~4.2pts over 30 days and options flow is modestly bullish (P/C 0.56) but not unusually so. Earnings are 47 days away — non-factor — and macro rates (10Y at 4.83%) are a structural headwind for a growth-oriented genomics name.

51. ?Sep 11, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

52. !Sep 11, 12:20 PMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    No hard veto conditions are triggered: earnings are 47 days away (outside the 14-day veto window), and no 8-K filings show guidance cuts, going-concern language, or fundamental deterioration. However, the signal score is net negative: the sector (Health Care/XLV) is underperforming SPY meaningfully (-4.24pts over 30 days, +1), options flow is modestly call-skewed with P/C of 0.56 (+1), but there is a large, concentrated insider sale by Director Keith Meister totaling ~$30.6M across five transactions on a single day (-1 clustered/large insider sale), the 10Y yield at 4.83% is a structural headwind for a growth/duration-sensitive name like ILMN (-1), earnings in 15–47 days creates an uncertainty premium (-1), and the drop is only 10.5% — below the 15% mean-reversion threshold, so no bonus there. Net score: +2 positive, -3 negative = -1. A net score of -1 argues against buying. The massive single-day insider sale by a director is particularly concerning as a conviction-dampening signal.

53. ❖Sep 11, 9:36 AMnewsvia finnhub

    This Copart Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday

    Analysts upgraded Copart, Orchestra BioMed, Illumina, Martin Marietta Materials and Waters, raising their price targets.

54. ?Sep 10, 4:26 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    No hard veto fires — earnings are 49 days away and no fundamental deterioration is evident from the 8-K filings. However, the signal scorecard is net negative: the drop is only 11.6% (below the +1 threshold of ≥15%), the sector (Health Care) is underperforming SPY on both 5d and 30d bases (+1), call/put ratio of 0.56 is modestly bullish but not unusually so (no z-score available, no +1 awarded), earnings in 15-30 day window doesn't apply but 49 days is clean (+1), yet macro headwinds are meaningful — 10Y at 4.78% is above the 4.5% structural headwind threshold for a growth/duration-sensitive genomics name like ILMN (-1), and insider activity is a significant negative: a single director (Meister) sold ~133,500 shares worth ~$30.6M in a single day, which is large and clustered even if potentially on a 10b5-1 plan (-1). Net score: approximately 0, which is marginal, and the strongest positive signal is not a cluster buy or unusual call flow. With a marginal net score and no compelling positive catalyst, rebound probability is set below the 0.50 buy threshold.

55. !Sep 10, 4:26 PMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    No hard veto fires — earnings are 49 days away and no fundamental deterioration is evident from the 8-K filings. However, the signal scorecard is net negative: the drop is only 11.6% (below the +1 threshold of ≥15%), the sector (Health Care) is underperforming SPY on both 5d and 30d bases (+1), call/put ratio of 0.56 is modestly bullish but not unusually so (no z-score available, no +1 awarded), earnings in 15-30 day window doesn't apply but 49 days is clean (+1), yet macro headwinds are meaningful — 10Y at 4.78% is above the 4.5% structural headwind threshold for a growth/duration-sensitive genomics name like ILMN (-1), and insider activity is a significant negative: a single director (Meister) sold ~133,500 shares worth ~$30.6M in a single day, which is large and clustered even if potentially on a 10b5-1 plan (-1). Net score: approximately 0, which is marginal, and the strongest positive signal is not a cluster buy or unusual call flow. With a marginal net score and no compelling positive catalyst, rebound probability is set below the 0.50 buy threshold.

56. ?Sep 10, 4:26 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ILMN is down 11.6% from its 30-day high with no news headlines explaining the drop, suggesting a macro/sector-driven move rather than a company-specific fundamental impairment. However, the evidence is notably thin: three empty-metrics 8-Ks provide no actionable fundamental data, and there is a significant insider selling event — a Director (Keith Meister) sold ~$30.6M worth of shares on 2026-08-27 across five transactions, which is a meaningful negative signal on a dip. Options flow is modestly bullish (P/C ratio 0.56), but not unusually so. Earnings are 49 days out, reducing binary risk. The Health Care sector is underperforming SPY modestly, suggesting the dip is partly sector-driven, which could limit idiosyncratic recovery potential.

57. !Sep 10, 4:26 PMsignalseverity 0.13

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ILMN is down 11.6% from its 30-day high with no news headlines explaining the drop, suggesting a macro/sector-driven move rather than a company-specific fundamental impairment. However, the evidence is notably thin: three empty-metrics 8-Ks provide no actionable fundamental data, and there is a significant insider selling event — a Director (Keith Meister) sold ~$30.6M worth of shares on 2026-08-27 across five transactions, which is a meaningful negative signal on a dip. Options flow is modestly bullish (P/C ratio 0.56), but not unusually so. Earnings are 49 days out, reducing binary risk. The Health Care sector is underperforming SPY modestly, suggesting the dip is partly sector-driven, which could limit idiosyncratic recovery potential.

58. ❖Sep 10, 7:03 AMnewsvia finnhub

    Transcriptome Sequencing Market - Global Forecast to 2035; Bulk RNA-Seq Maintains Its Technology Market Lead

    The global transcriptome sequencing market is projected to reach $11.8 billion by 2035, growing at a 7.3% CAGR from 2025 to 2035. Growth is driven by falling sequencing costs, precision medicine, drug discovery, biomarker development, single-cell and spatial transcriptomics, long-read RNA sequencing, and AI-powered analytics. Consumables, bulk RNA-seq, drug discovery applications, and pharmaceutical and biotechnology companies led the market in 2025. North America held the largest regional share

59. ❖Sep 10, 4:53 AMnewsvia finnhub

    This Meta Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

    Analysts upgraded SFNC, OBIO, and more.

60. ?Sep 9, 6:03 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 2: close $205.02 > MA150 $157.77 (+30.0%), MA rising, 11.6% off 52w high, vol 0.86× avg

61. ?Sep 9, 6:02 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $205.02 > MA150 $157.77 (+30.0%), MA rising, 11.6% off 52w high, vol 0.86× avg

62. ❖Sep 9, 4:34 PMnewsvia finnhub

    S&P Dow Jones Indices CEO on Index Restructuring

    Catherine Clay, CEO of S&P Dow Jones Indices, discusses the upcoming S&P reconstitution and rebalance, noting that the process is fully transparent and routine. She says market participants already know which names are entering and leaving the index, including Bloom Energy, Illumina and Everpure joining the S&P this month, and have ample time to adjust portfolios accordingly. She speaks with Romaine Bostick & Tyler Kendall on "The Close."

63. ?Sep 9, 4:25 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ILMN is down 11.6% from its 30-day high with no news headlines explaining the drop, suggesting a macro/sector-driven move rather than a company-specific fundamental impairment. However, the evidence is notably thin: three empty-metrics 8-Ks provide no actionable fundamental data, and there is a significant insider selling event — a Director (Keith Meister) sold ~$30.6M worth of shares on 2026-08-27 across five transactions, which is a meaningful negative signal on a dip. Options flow is modestly bullish (P/C ratio 0.56), but not unusually so. Earnings are 49 days out, reducing binary risk. The Health Care sector is underperforming SPY modestly, suggesting the dip is partly sector-driven, which could limit idiosyncratic recovery potential.

64. !Sep 9, 4:25 PMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ILMN is down 11.6% from its 30-day high with no news headlines explaining the drop, suggesting a macro/sector-driven move rather than a company-specific fundamental impairment. However, the evidence is notably thin: three empty-metrics 8-Ks provide no actionable fundamental data, and there is a significant insider selling event — a Director (Keith Meister) sold ~$30.6M worth of shares on 2026-08-27 across five transactions, which is a meaningful negative signal on a dip. Options flow is modestly bullish (P/C ratio 0.56), but not unusually so. Earnings are 49 days out, reducing binary risk. The Health Care sector is underperforming SPY modestly, suggesting the dip is partly sector-driven, which could limit idiosyncratic recovery potential.

65. ?Sep 9, 4:25 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    No hard veto fires — earnings are 49 days away and no fundamental deterioration is evident from the 8-K filings. However, the signal scorecard is net negative: the drop is only 11.6% (below the +1 threshold of ≥15%), the sector (Health Care) is underperforming SPY on both 5d and 30d bases (+1), call/put ratio of 0.56 is modestly bullish but not unusually so (no z-score available, no +1 awarded), earnings in 15-30 day window doesn't apply but 49 days is clean (+1), yet macro headwinds are meaningful — 10Y at 4.78% is above the 4.5% structural headwind threshold for a growth/duration-sensitive genomics name like ILMN (-1), and insider activity is a significant negative: a single director (Meister) sold ~133,500 shares worth ~$30.6M in a single day, which is large and clustered even if potentially on a 10b5-1 plan (-1). Net score: approximately 0, which is marginal, and the strongest positive signal is not a cluster buy or unusual call flow. With a marginal net score and no compelling positive catalyst, rebound probability is set below the 0.50 buy threshold.

66. !Sep 9, 4:25 PMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    No hard veto fires — earnings are 49 days away and no fundamental deterioration is evident from the 8-K filings. However, the signal scorecard is net negative: the drop is only 11.6% (below the +1 threshold of ≥15%), the sector (Health Care) is underperforming SPY on both 5d and 30d bases (+1), call/put ratio of 0.56 is modestly bullish but not unusually so (no z-score available, no +1 awarded), earnings in 15-30 day window doesn't apply but 49 days is clean (+1), yet macro headwinds are meaningful — 10Y at 4.78% is above the 4.5% structural headwind threshold for a growth/duration-sensitive genomics name like ILMN (-1), and insider activity is a significant negative: a single director (Meister) sold ~133,500 shares worth ~$30.6M in a single day, which is large and clustered even if potentially on a 10b5-1 plan (-1). Net score: approximately 0, which is marginal, and the strongest positive signal is not a cluster buy or unusual call flow. With a marginal net score and no compelling positive catalyst, rebound probability is set below the 0.50 buy threshold.

67. ❖Sep 9, 2:38 PMnewsvia finnhub

    Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now

    TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.

68. ❖Sep 9, 10:32 AMnewsvia finnhub

    Dear Illumina Stock Fans, Mark Your Calendars for September 21

    Illumina stock is joining the S&P 500 on Sept. 21. Here's why that matters, what's fueling growth, and what investors should watch next.

69. ❖Sep 9, 10:30 AMnewsvia finnhub

    Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain?

    FDA approval for TactiFlex Duo expands ABT's AFib ablation portfolio with dual PFA and RF energy options, supporting broader U.S. adoption.

70. ❖Sep 9, 10:10 AMnewsvia finnhub

    Dear Everpure Stock Fans, Mark Your Calendars for September 21

    Everpure stock is joining the S&P 500 on Sept. 21. Here's what's changing, why it matters, and what's driving Everpure's growth this year.

71. ❖Sep 9, 8:40 AMnewsvia finnhub

    This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

    Analysts upgraded Sagimet, Figure, Illumina, Martin Marietta and Waters, raising price targets and improving ratings.

72. ❖Sep 9, 8:30 AMnewsvia finnhub

    Encoded Therapeutics Raises $275 Million in Series F Financing to Advance ETX101 Through Pivotal Development and Accelerate its Precision Genetic Medicines Neurology Pipeline

    SOUTH SAN FRANCISCO, Calif., September 09, 2026--Encoded Therapeutics Raises $275 Million in Series F Financing to Advance Precision Genetic Medicines Neurology Pipeline

73. ❖Sep 9, 5:28 AMnewsvia finnhub

    UBS Upgrades Illumina to Buy, Raises Price Target to $260

    UBS analyst Doug Schenkel upgrades Illumina (NASDAQ:ILMN) from Neutral to Buy and raises the price target from $135 to $260.

74. ❖Sep 8, 8:38 PMnewsvia finnhub

    3 Stocks Soon Joining the S&P 500

    The S&P 500 is set for another shakeup, with Bloom Energy (BE), Everpure (P), and Illumina (ILMN) all joining in the next quarterly rebalancing near the end of September.

75. ?Sep 8, 6:03 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 2: close $211.11 > MA150 $157.30 (+34.2%), MA rising, 8.9% off 52w high, vol 0.87× avg

76. ?Sep 8, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $211.11 > MA150 $157.30 (+34.2%), MA rising, 8.9% off 52w high, vol 0.87× avg

77. ?Sep 4, 6:02 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $218.12 > MA150 $156.83 (+39.1%), MA rising, 5.9% off 52w high, vol 0.88× avg

78. ?Sep 4, 6:01 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 2: close $218.12 > MA150 $156.83 (+39.1%), MA rising, 5.9% off 52w high, vol 0.88× avg

79. ?Sep 4, 11:00 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ILMN is down 2.20% with 285 minutes remaining — meaningful time for continuation but no catalytic news to anchor the move. The macro context shows 5-year forward inflation expectations elevated (~1.7σ above trend), which is a mild headwind for rate-sensitive growth/genomics names like ILMN, as higher real rate expectations compress long-duration equity valuations. No headlines provide a counter-narrative or reversal catalyst. The move itself (~$4.88 decline) represents real selling flow, but without a clear fundamental trigger the conviction level is moderate. With ~4.75 hours left, there is ample time for continuation, but the absence of news also means the move could fade if it was driven by thin technical selling rather than fundamental repricing. On balance, the macro backdrop is modestly supportive of further downside, time remaining is not a constraint, and no reversal signals are present. Probability sits just above neutral — this is a borderline continuation setup.

80. ?Sep 2, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $213.26 > MA150 $155.87 (+36.8%), MA rising, 8.0% off 52w high, vol 0.80× avg

81. ?Sep 2, 6:03 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 2: close $213.26 > MA150 $155.87 (+36.8%), MA rising, 8.0% off 52w high, vol 0.80× avg

82. ?Sep 2, 10:26 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ILMN is up 1.82% with 319 minutes remaining — meaningful time left in the session for continuation. The move is moderate, not extended enough to suggest an imminent exhaustion reversal, but also not the kind of strong 3-5%+ surge that signals outsized conviction. No news catalyst is identifiable, which is neutral per guidance. The macro context shows 5-year forward inflation expectations (T5YIFR) elevated at 1.7σ above trend — this is a modest headwind for rate-sensitive and growth-oriented names like ILMN (genomics/biotech tends to be long-duration), which could temper upside into the close as bond markets reprice. However, this is a mild rather than severe macro drag. No reversal signals are noted. With no strong reason to fade and ample time remaining, the default is to respect the intraday momentum, though conviction is limited given the macro rate sensitivity and absence of a clear catalyst. Probability set just above the 0.5 threshold.

83. ?Sep 2, 7:06 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ILMN is down 10.6% from its 30-day high, a moderate dip without any confirmed fundamental catalyst — no news headlines, no earnings guidance cut, and no SEC filings with material negative disclosures. The Health Care sector ranks 2nd of 11 by 30-day relative strength with a solid +3.73pts vs SPY over 30 days, suggesting the dip is somewhat idiosyncratic rather than purely sector-driven, which warrants scrutiny. The most significant negative signal is the substantial insider selling by Director Keith Meister on 2026-08-21, totaling approximately $53M across five transactions — this is a large, concentrated sale on a stock that is already declining, a meaningful bearish signal even accounting for potential 10b5-1 plan noise.

84. ?Sep 1, 6:03 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 2: close $207.13 > MA150 $155.44 (+33.3%), MA rising, 10.6% off 52w high, vol 1.32× avg

85. ?Sep 1, 6:02 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $207.13 > MA150 $155.44 (+33.3%), MA rising, 10.6% off 52w high, vol 1.32× avg

86. ?Sep 1, 4:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ILMN is down 10.6% from its 30-day high, a moderate dip without any confirmed fundamental catalyst — no news headlines, no earnings guidance cut, and no SEC filings with material negative disclosures. The Health Care sector ranks 2nd of 11 by 30-day relative strength with a solid +3.73pts vs SPY over 30 days, suggesting the dip is somewhat idiosyncratic rather than purely sector-driven, which warrants scrutiny. The most significant negative signal is the substantial insider selling by Director Keith Meister on 2026-08-21, totaling approximately $53M across five transactions — this is a large, concentrated sale on a stock that is already declining, a meaningful bearish signal even accounting for potential 10b5-1 plan noise.

87. ?Sep 1, 4:22 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    No hard veto triggered (drop is only 10.1%, no earnings within 14 days, no disclosed fundamental deterioration in the empty 8-Ks). Signal scoring: +1 for no earnings within 30 days (next is 57 days out), +1 for neutral-to-low VIX (7th percentile, low fear environment), -1 for high 10Y yield (4.73%, above the 4.5% threshold — a structural headwind for ILMN, a long-duration genomics/biotech growth name), -1 for large concentrated insider sales (Director Keith Meister sold ~$53M across five same-day transactions on 2026-08-21, which is large and clustered even if potentially 10b5-1), -1 for idiosyncratic single-stock weakness (Health Care sector is ranked 2nd of 11 by 30d relative strength with a +3.73pt edge vs SPY, meaning ILMN is underperforming its own outperforming sector — the dip is not sector-driven), and 0 for absent options flow and no news. Net signal score: -1. With a net score of -1 and the insider sale magnitude being unusually large ($53M in a single day from one director), the base-rate anchor of ~55-60% is pulled meaningfully below the buy threshold. The company's financial soundness is not confirmed by the available empty 8-K filings, and the significant director-level liquidation is a meaningful negative signal.

88. ?Sep 1, 3:26 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    No hard veto triggered (drop is only 10.1%, no earnings within 14 days, no disclosed fundamental deterioration in the empty 8-Ks). Signal scoring: +1 for no earnings within 30 days (next is 57 days out), +1 for neutral-to-low VIX (7th percentile, low fear environment), -1 for high 10Y yield (4.73%, above the 4.5% threshold — a structural headwind for ILMN, a long-duration genomics/biotech growth name), -1 for large concentrated insider sales (Director Keith Meister sold ~$53M across five same-day transactions on 2026-08-21, which is large and clustered even if potentially 10b5-1), -1 for idiosyncratic single-stock weakness (Health Care sector is ranked 2nd of 11 by 30d relative strength with a +3.73pt edge vs SPY, meaning ILMN is underperforming its own outperforming sector — the dip is not sector-driven), and 0 for absent options flow and no news. Net signal score: -1. With a net score of -1 and the insider sale magnitude being unusually large ($53M in a single day from one director), the base-rate anchor of ~55-60% is pulled meaningfully below the buy threshold. The company's financial soundness is not confirmed by the available empty 8-K filings, and the significant director-level liquidation is a meaningful negative signal.

89. ?Sep 1, 12:25 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ILMN is down 2.57% intraday with no attributable headline, suggesting broad market or sector pressure rather than stock-specific news. The macro context shows 2-year yields elevated at 2.0σ above trend, which is a headwind for long-duration growth/tech names like ILMN (genomics/biotech fits this profile). However, with 200 minutes remaining (roughly 3+ hours), there is meaningful time for continuation but also for mean reversion. The absence of a catalyst makes the move harder to sustain, but elevated rates environment adds mild structural pressure. No reversal pattern is evident from the data provided. Momentum is modestly in favor of continuation given the macro backdrop and the size of the move suggesting real institutional selling, but conviction is low — rating this a marginal continuation at 0.52.

90. ?Aug 31, 6:03 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 2: close $213.80 > MA150 $155.08 (+37.9%), MA rising, 7.8% off 52w high, vol 1.61× avg

91. ?Aug 31, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $213.80 > MA150 $155.08 (+37.9%), MA rising, 7.8% off 52w high, vol 1.61× avg

92. ?Aug 31, 9:40 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ILMN is down 5.31% intraday — a meaningful move indicating real selling pressure with conviction behind it. No headlines are available to explain the move, but absence of news is not a disqualifier; large institutional flows often precede public information or reflect portfolio repositioning. The macro context (elevated mortgage rates) is not directly relevant to ILMN, a genomics/life sciences name, so no macro tailwind or headwind is introduced. With 365 minutes remaining (effectively the full remaining session), there is ample time for continuation. At this stage of the day the move is still relatively fresh and not yet exhausted. The primary uncertainty is whether this is a gap-and-fade pattern or sustained distribution — without volume data or intraday chart context, we cannot confirm sustained selling, which keeps the probability in the moderate range rather than the high-conviction zone. No reversal signals are evident. On balance, the size of the move and time remaining support a modest continuation bias to the downside.

93. ❖Aug 7, 12:00 PMnewsvia finnhub

    What Makes Illumina (ILMN) a New Strong Buy Stock

    Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

94. ▣Aug 6, 8:00 PMjournalstop

    Agent 2 — Adaptive closed long 91 @ $188.03 (+$1,828.62)

    Long trailing stop: close $188.03 ≤ trailing floor $190.74 (peak × 0.93)

95. ❖Aug 6, 7:01 PMnewsvia finnhub

    Caris Life Sciences: Guidance Raised, Valuation Still Attractive

    Caris Life Sciences (CAI) Q2 beats with raised guidance, margin expansion and Caris Detect launch.

96. ❖Aug 5, 4:05 PMnewsvia finnhub

    Standard BioTools Reports Second Quarter 2026 Financial Results

    BOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026. Recent Highlights: Second quarter 2026 revenue of $20.1 million1% improvement in operating loss and 84% improvement in adjusted EBITDA year-over-yearMerger with Treeline Biosciences progressing toward stockholder vote and anticipated to close before year-end 2026 “We remain on track to close our merger

97. ❖Aug 5, 1:45 PMnewsvia finnhub

    Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today

    Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 3.84% on an annualized basis producing an average annual return of 13.26%. Currently, Illumina has a market capitalization of $30.65 billion.

98. ❖Aug 5, 10:53 AMnewsvia finnhub

    Illumina (ILMN) Rose on Strong Clinical Momentum

    Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its “Mid Cap Strategy”. A copy of the Q2 2026 investor letter can be downloaded here. In the quarter, equity markets posted strong returns as resilient economic growth and robust corporate earnings supported investor sentiment, although AI-related companies continued to dominate market […]

99. ❖Aug 5, 9:40 AMnewsvia finnhub

    Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls

    Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls

100. ❖Aug 3, 8:15 PMnewsvia finnhub

     Illumina (ILMN) Q2 2026 Earnings Call Transcript

     Clinical momentum and NovaSeq X placements drive revenue guidance raise.

101. ❖Aug 3, 5:33 PMnewsvia finnhub

     3 Cash-Producing Stocks That Concern Us

     While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

102. ❖Aug 3, 1:21 PMnewsvia finnhub

     Canaccord Genuity Maintains Hold on Illumina, Raises Price Target to $205

     Canaccord Genuity analyst Kyle Mikson maintains Illumina (NASDAQ:ILMN) with a Hold and raises the price target from $190 to $205.

103. ❖Aug 3, 10:49 AMnewsvia finnhub

     Citigroup Maintains Sell on Illumina, Raises Price Target to $113

     Citigroup analyst Joanne Wuensch maintains Illumina (NASDAQ:ILMN) with a Sell and raises the price target from $95 to $113.

104. ❖Aug 3, 9:15 AMnewsvia finnhub

     Illumina, Inc. (ILMN) Hits Fresh High: Is There Still Room to Run?

     Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

105. ❖Aug 3, 7:59 AMnewsvia finnhub

     Piper Sandler Reiterates Overweight on Illumina, Raises Price Target to $225

     Piper Sandler analyst David Westenberg reiterates Illumina (NASDAQ:ILMN) with a Overweight and raises the price target from $200 to $225.

106. ❖Aug 2, 8:15 PMnewsvia finnhub

     Why Illumina (ILMN) Is Up 5.7% After Raising 2026 Revenue Outlook On Clinical Sequencing

     In late July 2026, Illumina reported second-quarter results showing revenue of US$1,159 million versus US$1,059 million a year earlier, while net income eased to US$207 million from US$235 million and diluted earnings per share from continuing operations slipped to US$1.35 from US$1.49. At the same time, the company lifted its 2026 revenue outlook to US$4.60 billion–US$4.64 billion and guided third-quarter revenue of US$1.14 billion–US$1.16 billion, underscoring how clinical sequencing...

107. ▣Aug 2, 8:00 PMjournalrotation

     Agent 17 — 52-Week High Momentum closed long 26 @ $198.30 (+$374.66)

     52-Week High monthly rebalance. Position dropped from top 20.

108. ❖Aug 2, 4:07 PMnewsvia finnhub

     Can Illumina (ILMN) Hold Its Price As Cash Flow And Earnings Clash?

     Illumina stock has more than doubled over the past year, yet valuation checks are split, with a Discounted Cash Flow (DCF) estimate pointing to upside while market multiples lean rich at the current US$205.10 share price. Illumina has returned 116.7% over the past year, which puts extra focus on whether today’s price still offers a reasonable margin between market value and business fundamentals. Stronger demand for clinical sequencing can support expectations for future cash flows, while...

109. ❖Aug 2, 2:10 PMnewsvia finnhub

     Illumina (ILMN) Could Be 19% Overvalued Following Its Q2 Beat And Guidance Raise

     Illumina (ILMN) is back in focus after its Q2 2026 results beat expectations on both revenue and earnings, prompting the company to lift full year guidance and outline priorities in clinical sequencing and multi omics. See our latest analysis for Illumina. Illumina’s recent guidance raise and Q2 beat come after a strong run in the stock, with a 90 day share price return of 47.16% and a 1 year total shareholder return of 116.67%. However, the 5 year total shareholder return is down 57.56%,...

110. ❖Aug 1, 1:28 PMnewsvia finnhub

     Is Grail (GRAL) Stock a Buy, Sell, or Hold at Under $70?

     The developer of blood-based cancer tests still has a bright future.

111. ❖Jul 31, 8:03 PMnewsvia finnhub

     Illumina Q2 Earnings Call Highlights

     Illumina (NASDAQ:ILMN) raised its 2026 revenue and earnings outlook after reporting second-quarter results that exceeded its expectations, supported by clinical sequencing demand, elevated NovaSeq X placements and higher consumables volume. Second-quarter revenue totaled $1.16 billion, up 9.5% from

112. ❖Jul 31, 6:43 PMnewsvia finnhub

     ILMN Q2 Deep Dive: Clinical Strength, Platform Expansion, and Strategic Focus Drive Guidance Lift

     Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates.

113. ❖Jul 31, 4:51 PMnewsvia finnhub

     Illumina CEO on Genomic Sequencing Opportunities and AI

     Illumina CEO Jacob Thaysen discusses the company's earnings, genomic medicine opportunities and the potential for artificial intelligence in life sciences on "Bloomberg The Close."

114. ❖Jul 31, 11:09 AMnewsvia finnhub

     RBC Capital Maintains Outperform on Illumina, Raises Price Target to $230

     RBC Capital analyst Dan Leonard maintains Illumina (NASDAQ:ILMN) with a Outperform and raises the price target from $170 to $230.

115. ❖Jul 31, 11:01 AMnewsvia finnhub

     Illumina, Inc. 2026 Q2 - Results - Earnings Call Presentation

     2026-07-31. The following slide deck was published by Illumina, Inc.

116. ❖Jul 31, 9:39 AMnewsvia finnhub

     JP Morgan Maintains Overweight on Illumina, Raises Price Target to $230

     JP Morgan analyst Casey Woodring maintains Illumina (NASDAQ:ILMN) with a Overweight and raises the price target from $220 to $230.

117. ❖Jul 31, 8:51 AMnewsvia finnhub

     TD Cowen Maintains Hold on Illumina, Raises Price Target to $210

     TD Cowen analyst Dan Brennan maintains Illumina (NASDAQ:ILMN) with a Hold and raises the price target from $192 to $210.

118. ❖Jul 31, 8:30 AMnewsvia finnhub

     Illumina, Inc. Q2 2026 Earnings Call Summary

     Moby summary of Illumina, Inc.'s Q2 2026 earnings call

119. ❖Jul 31, 6:01 AMnewsvia finnhub

     Guggenheim Maintains Buy on Illumina, Raises Price Target to $226

     Guggenheim analyst Subbu Nambi maintains Illumina (NASDAQ:ILMN) with a Buy and raises the price target from $200 to $226.

120. ❖Jul 31, 5:55 AMnewsvia finnhub

     Stifel Maintains Buy on Illumina, Raises Price Target to $225

     Stifel analyst Daniel Arias maintains Illumina (NASDAQ:ILMN) with a Buy and raises the price target from $155 to $225.

121. ❖Jul 31, 3:55 AMnewsvia finnhub

     Barclays Maintains Underweight on Illumina, Raises Price Target to $160

     Barclays analyst Luke Sergott maintains Illumina (NASDAQ:ILMN) with a Underweight and raises the price target from $145 to $160.

122. ❖Jul 31, 1:04 AMnewsvia finnhub

     Illumina Inc (ILMN) (Q2 2026) Earnings Call Highlights: Strong Clinical Growth Drives Revenue ...

     Illumina Inc (ILMN) reports 9.5% revenue growth in Q2 2026, led by robust clinical demand and NovaSeq X placements, prompting an upward revision to full-year EPS guidance.

123. ❖Jul 30, 9:32 PMnewsvia finnhub

     Illumina (ILMN) Q2 2026 Earnings Call Transcript

     Clinical momentum and NovaSeq X placements drive revenue guidance raise.

124. ❖Jul 30, 7:30 PMnewsvia finnhub

     Illumina (ILMN) Reports Q2 Earnings: What Key Metrics Have to Say

     The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

125. ❖Jul 30, 6:00 PMnewsvia finnhub

     Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates

     Illumina (ILMN) delivered earnings and revenue surprises of +6.50% and +3.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

126. ❖Jul 30, 5:09 PMnewsvia finnhub

     Illumina (NASDAQ:ILMN) Beats Q2 Estimates but Shares Slide 6% After-Hours

     Illumina beat Q2 estimates with $1.159B revenue and $1.31 EPS, but shares fell 6% after-hours due to lack of forward guidance.

127. ❖Jul 30, 4:21 PMnewsvia finnhub

     Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full-Year Outlook Slightly Exceeds Expectations

     Genomics company Illumina (NASDAQ:ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates.

128. ❖Jul 30, 4:05 PMnewsvia finnhub

     Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026

     Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026.

129. ❖Jul 30, 3:53 PMnewsvia finnhub

     Illumina, Inc. (ILMN) Q2 2026 Earnings Call Transcript

     Illumina, Inc. (ILMN) Q2 2026 Earnings Call July 30, 2026 4:30 PM EDTCompany ParticipantsConor Noel McNamara - VP of Investor RelationsJacob Thaysen - CEO...

130. ❖Jul 30, 1:49 PMnewsvia finnhub

     Scale AI names Francis deSouza as new CEO

     Francis deSouza, who previously served as COO and president of security products at Google Cloud, takes over on Aug. 10

131. ❖Jul 30, 12:13 PMnewsvia finnhub

     Illumina Raises FY2026 Adj EPS Guidance from $5.15-$5.30 to $5.30-$5.40 vs $5.23 Est; Raises FY2026 Sales Guidance from $4.520B-$4.620B to $4.600B-$4.640B vs $4.566B Est

     Illumina (NASDAQ:ILMN) raises FY2026 Adj EPS guidance from $5.15-$5.30 to $5.30-$5.40 vs $5.23 analyst estimate. Raises FY2026 sales outlook from $4.520 billion-$4.620 billion to $4.600 billion-$4.640 billion vs $4.566

132. ❖Jul 30, 11:04 AMnewsvia finnhub

     Scale AI taps former Google Cloud executive as CEO

     Scale AI said on Thursday it had named former Google Cloud executive Francis DeSouza as ‌chief executive officer, effective August 10, as the ‌AI company looks to expand its data and applications businesses. DeSouza will succeed Jason ​Droege, who has served as interim CEO since June last year. Droege will work with deSouza in the coming months to support the transition, Scale said.

133. ▢Jul 29, 8:00 PMjournal

     Agent 7 — Day Trader opened long 14 @ $198.47

134. ▣Jul 29, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 14 @ $203.64 (+$72.38)

     EOD forced close — day trader never carries overnight

135. ▢Jul 1, 8:00 PMjournal

     Agent 17 — 52-Week High Momentum opened long 26 @ $183.89

136. ▢Jun 9, 8:00 PMjournal

     Agent 2 — Adaptive opened long 91 @ $167.94

137. ▣Jun 7, 8:00 PMjournalstop

     options_momentum closed long 70 @ $10.96 (+$229.92)

     Stop: premium $10.96 ≤ trailing floor $16.67 (peak $22.22 × 0.75)

138. ▣Jun 7, 8:00 PMjournalmanual

     options_momentum closed long 70 @ $18.10 (+$790.03)

     Stop: premium $14.25 ≤ trailing floor $16.67 (peak $22.22 × 0.75)

139. ▣Jun 7, 8:00 PMjournalmanual

     options_momentum closed long 30 @ $6.89 (+$2.03)

     Stop: premium $5.26 ≤ trailing floor $8.11 (peak $10.81 × 0.75)

140. ▣May 31, 8:00 PMjournalrotation

     Agent 17 — 52-Week High Momentum closed long 23 @ $164.47 (+$34.04)

     52-Week High monthly rebalance. Position retained in target set; re-entered at equal weight.

141. ▣May 28, 8:00 PMjournaltarget

     options_momentum closed long 30 @ $15.99 (+$249.66)

     De-risk: premium $15.99 ≥ 2.0× entry $7.67. Selling 30/100 contracts; trailing the remainder.

142. ▢May 28, 8:00 PMjournal

     Agent 7 — Day Trader opened long 11 @ $158.70

143. ▣May 28, 8:00 PMjournaltarget

     Agent 7 — Day Trader closed long 11 @ $163.49 (+$52.69)

     Long target: close $163.49 ≥ target $163.46

144. ▢May 28, 8:00 PMjournal

     Agent 17 — 52-Week High Momentum opened long 23 @ $162.99

145. ▢May 28, 8:00 PMjournal

     options_momentum opened long 70 @ $6.82

146. ▢May 28, 8:00 PMjournal

     options_momentum opened long 30 @ $6.82

147. ▢May 27, 8:00 PMjournal

     Agent 7 — Day Trader opened long 12 @ $156.03

148. ▣May 27, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 12 @ $157.33 (+$15.66)

     EOD forced close — day trader never carries overnight

149. ▢May 26, 8:00 PMjournal

     options_momentum opened long 30 @ $7.67

150. ▢May 26, 8:00 PMjournal

     options_momentum opened long 70 @ $7.67